Results 171 to 180 of about 27,407 (265)

Ertugliflozin - SGLT2 inhibitor [PDF]

Interní medicína pro praxi, 2019
openaire   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Multi-Chamber Reverse Remodeling and Hemodynamic Force Realignment After SGLT2 Inhibitor Initiation in Real-World Heart Failure. [PDF]

J Cardiovasc Dev Dis
Prosperi S, Monosilio S, D'Amato A, Angotti D, Filomena D, Netti L, Tonti G, Pedrizzetti G, Cimino S, Badagliacca R, Severino P, Vizza CD, Maestrini V.   +12 more
europepmc   +1 more source

Systematic Comparison of High‐Fat Diet– and Streptozotocin‐Induced Prediabetic Obese C57BL/6J Mouse Models: A Sex‐Based Protocol Optimization Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Animal models of prediabetes (Pre‐DM) are essential for studying metabolic disease and testing therapies, yet high‐fat diet (HFD) and HFD‐plus‐streptozotocin (STZ) protocols vary in feeding duration, STZ dose, and diagnostic criteria and rarely account for sex.
Min Xu, Chao Ke, Yangkun Liu, Wenying Shi, Yang Cao, Zhengyu Li, Yi Xiao, Wei Zhang   +7 more
wiley   +1 more source

Fatal Hypoglycemia in a Nondiabetic Patient With End-Stage Familial Hypertrophic Cardiomyopathy on SGLT2 Inhibitor Therapy. [PDF]

JACC Case Rep
Li Y, Zhong L.
europepmc   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, Bisceglia I, Tedeschi A, Scherillo M, Santagata J, Oliva S, Dessalvi CC, Forte P, D'Ambrosio C, Matola TD, Parmentola R, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Repurposing SGLT2 inhibitors [PDF]

Nature Reviews Drug Discovery, 2018
openaire   +1 more source

The ‘Slow Burn’ Phenotype: How Relative Caloric Intake Reveals Hidden Cardiovascular Risk Beyond BMI

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Body mass index (BMI) inadequately captures heterogeneity in cardiovascular (CV) risk. We hypothesised that a ‘Slow Burn’ phenotype, defined as lower‐than‐expected energy intake relative to BMI, age, and sex, identifies individuals at elevated CV risk across the BMI spectrum.
Yongin Cho, Jong Hyun Jhee, Jong Ho Jhee, Hye‐Sun Park   +3 more
wiley   +1 more source